ABI
NBIX icon

Adamant Biomedical Investments’s Neurocrine Biosciences NBIX Stock Holding History

Adamant Biomedical Investments’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$1M Hold
45,000
– – 0.24% 82
2014
Q3 		$705K Buy
+45,000
New +$673K 0.18% 84

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Adamant Biomedical Investments's NBIX Position: Q4 2014 in Review

Adamant Biomedical Investments held its Neurocrine Biosciences (NBIX) position steady in Q4 2014 at 45,000 shares worth $1M. The position accounts for 0.24% of the portfolio, ranked #82.

Adamant Biomedical Investments first reported a position in NBIX in Q3 2014 and has held it in 2 quarters since. 133 funds tracked by Wall St. Rank hold NBIX as of Q4 2014.

  • Adamant Biomedical Investments held 45,000 shares of Neurocrine Biosciences worth $1M as of Q4 2014.
  • Adamant Biomedical Investments left its Neurocrine Biosciences share count unchanged in Q4 2014.
  • Neurocrine Biosciences made up 0.24% of Adamant Biomedical Investments's portfolio in Q4 2014, its #82 holding.
  • Adamant Biomedical Investments first reported a position in Neurocrine Biosciences in Q3 2014 and has held it in 2 quarters since.
  • 133 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.